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After a diagnosis (by fine needle, core needle, incisional or exci-
sional biopsy) of in situ or invasive breast cancer, thousands of
women undergo mastectomies each year in order to obtain optimal
local control of their disease. Two of the primary reasons for
performing mastectomy are large tumour size and inability to
obtain negative tumour margins after one or more excisional
biopsies. Many women presumed to have large tumours by clinical
assessment undergo mastectomy after diagnosis by fine or core
needle aspiration. Unfortunately, clinical assessment may under-
or overestimate actual tumour size (Harris et al, 1993).
In the recently operated breast, mammography and breast exam-
ination are generally of little help in predicting residual disease. A
number of pathologic factors in the diagnostic biopsy have been
associated with residual disease/local failure in the breast,
including positive margins, gross multicentricity, extensive intra-
ductal carcinoma, age under 35–40, and invasive lobular carci-
noma (Lagios, 1992; Harris et al, 1993). Despite the currently
available markers, approximately half of the women who undergo
mastectomy for presumed residual disease will not have disease
when the breast is investigated microscopically. Additional
markers are needed to better tailor therapy for these women.
Present efforts to evaluate the breast directly either through
evaluation of tissue or individual cells have been hindered because
the analysis of these specimens generally required an invasive
procedure. The adult, non-pregnant, non-lactating breast secretes
fluid into the breast ductal system. This fluid can be obtained
through aspiration of the nipple with a modified breast pump.
Refinements in the ability to obtain this fluid, as well as epidemi-
ologic studies to identify subjects most likely to yield NAF, have
been ongoing for over 20 years. Nipple aspiration has the attrac-
tiveness of quickly, painlessly, and non-invasively obtaining both
breast epithelial cells (the cells at risk for transformation to breast
cancer), as well as secreted proteins, which are concentrated in
the fluid. We are now able to obtain cellular NAF samples (³ ten
breast epithelial cells on a slide) in the majority of subjects
(Sauter et al, 1997). Those samples containing few or no breast
epithelial cells are also informative, for we have shown that NAF
cytology of low cellularity is associated (P = 0.001) with low
breast cancer risk (Sauter et al, 1997). We have also demonstrated
that secreted proteins in NAF, such as prostate-specific antigen
(PSA) (Sauter et al, 1996), can be analysed and are associated 
(P = 0.002) with risk.
The goal of this study was to determine if biological markers of
breast cancer risk in NAF from mastectomy specimens were asso-
ciated with residual disease in the breast and/or primary tumour
size. We performed nipple aspiration on fresh mastectomy speci-
mens rather than on subjects prior to mastectomy for practical
reasons. There is generally only a short interval of a few days to a
few weeks between the time of breast cancer diagnosis and
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LA in March 1998.mastectomy, so an additional visit to the clinic for breast aspiration
prior to mastectomy may be difficult. The subjects to be aspirated
are very anxious due to their recent diagnosis of breast cancer, are
already required to undergo a number of clinical tests (blood tests,
X-rays, etc.) and may be reluctant to undergo an additional test
with unproven benefit. By aspirating the breast immediately after
removal we avoided these potential problems.
Each of the markers chosen for analysis has proven or suspected
importance in breast cancer. We have previously demonstrated that
NAF cytology and PSA levels in NAF are associated with breast
cancer risk (Sauter et al, 1996, 1997). EGF stimulates breast
cancer cell growth (Earp et al, 1995). CEA is frequently found in
subjects with metastatic breast cancer and, in combination with
other markers, is useful in predicting breast cancer recurrence
(Leis, 1991). Changes in DNA content and cell cycle parameters,
including DNA index, S phase fraction, and G2/M, are breast
cancer prognostic markers frequently used in clinical practice
(Yeatman and Bland, 1991). PGDS is an enzyme recently found in
breast cyst fluid and in breast tumours, with potential as a marker
of breast cancer risk (Melegos et al, 1991). If markers in NAF
predictive of residual cancer and/or of tumour size are identified,
they may prove useful to help guide therapy regarding further
surgery and/or radiation therapy.
MATERIALS AND METHODS
Subjects
Ninety-seven specimens from 95 subjects aged 30–79 years
(median 52 years) were collected for the study between January
1995 and July 1997 after approval of the Fox Chase Institutional
Review Board. Eighty-one per cent of the subjects were white,
15% African-American and 4% Hispanic. Each breast had under-
gone needle or excisional biopsy demonstrating ductal carcinoma
in situ (DCIS) or invasive cancer. A mastectomy was performed
a median of 22 days (range 2–84 days) after excisional biopsy,
with the exception of three subjects who received neoadjuvant
chemotherapy prior to mastectomy. NAF was obtained from 96/97
specimens. Mastectomy specimens were categorized as having
residual cancer if either invasive carcinoma (IC) or DCIS was
present in the breast, or no residual cancer if neither IC or DCIS
was present. (This category included subjects whose specimens
contained lobular carcinoma in situ (LCIS), atypical hyperplasia
(AH), hyperplasia without atypia, or normal breast tissue.)
Subjects were also grouped by the method of disease diagnosis:
needle biopsy (either fine or core) or excisional biopsy. No subject
underwent incisional biopsy. If an individual underwent both
needle and excisional biopsy prior to mastectomy, they were
placed in the excisional biopsy group.
The primary indication for mastectomy for each of the subject
specimens is outlined in Table 1. For subjects diagnosed by needle
biopsy (NB), all were presumed to have residual disease. Sixteen
of 24 (67%) subjects diagnosed by NB underwent mastectomy
rather than excisional biopsy due to large tumour size, while
subject preference was the primary reason for mastectomy rather
than excisional biopsy in the other eight subjects. The presence of
breast cancer at or near the surgical margin, or an unknown margin
status, was the deciding factor in each of the subjects who under-
went mastectomy after excisional biopsy. After excisional biopsy,
margins were involved in 52/72 (72%), close in 18/72 (25%), or
unknown in 2/72 (3%). Pathology records were also reviewed for
the presence in each breast cancer of an extensive intraductal
component, for multifocality and for multicentricity.
Aspiration technique
Nipple fluid was aspirated by a trained physician or nurse clinician
using a modified breast pump (Sauter et al, 1996). The mastec-
tomy specimen was transported from the operating room to the
histology facility immediately after resection. The breast nipple
was cleansed with alcohol, the plunger of the aspiration device was
withdrawn to the 7 ml level and held for 15 s. Fluid in the form of
droplets was collected in capillary tubes. The quantity of fluid
varied from 1 ml to 200 ml.
If keratin plugs rather than NAF were obtained after suction was
completed, the plugs were removed with an alcohol swab and
suctioning repeated. On some occasions, this procedure was
repeated two or three times to remove the plugs before fluid was
obtained. In order to obtain additional fluid, the nipple was gently




The NAF was collected in 50-ml capillary tubes and rinsed into a
container with 1 ml of 3% polyethylene glycol in ethanol–
isopropanol. The specimen was then cytocentrifuged onto ten
glass slides. Three of the slides were used for cytological examina-
tion. If the slides contained < 10 epithelial cells, two additional
slides were examined. The remaining slides (five or seven) were
stored for biomarker studies. The slides selected for cytological
examination were washed twice in 95% ethanol for 10 min each,
rehydrated in tap water and stained by the Papanicolaou method.
Specimen interpretation
The Papanicolaou-stained smears were examined by a cytopathol-
ogist (HE) experienced with breast cytology. The examiner was
not aware of the histology of each specimen. Moreover, since the
NAF specimens analysed in this study were mixed with specimens
from subjects with an intact breast, the examiner was not aware of
which NAF specimens were from mastectomies. Each specimen
was designated as containing scant epithelial cells (class I), normal
epithelial cells (class IIA), hyperplasia without atypia (class IIB),
atypia (class III), or malignant cells (class IV), using criteria previ-
ously described (Sauter et al, 1997). This is a modification of
terminology used by King et al (1983), and is to be differentiated
from the Papanicolaou classification.
NAF to identify markers of breast cancer 1223
British Journal of Cancer (1999) 81(7), 1222–1227 © 1999 Cancer Research Campaign
Table 1 Primary indication for mastectomy provided by the clinical record
Indication Needle biopsy Excisional biopsy
Carcinoma size 18 0
Patient preference 6 0
Involved margin NA 52
Close (< 2 mm) margin NA 18
Unknown margin NA 2
NA: not applicable.Histology
Specimen preparation
After breast aspiration was completed, the mastectomy specimen
was fixed in 10% neutral buffered formalin for 16–24 h and
embedded in paraffin wax. Eighteen to 20 representative blocks
were prepared, and one 5-mm slide per block was cut and stained
with haematoxylin and eosin (H&E).
Specimen interpretation
Histological review of each H&E slide from the needle aspiration,
excisional biopsy and mastectomy was performed. Margin status
was assessed in the excisional biopsies. A margin was defined as
positive if tumour was present at the margin, close if tumour was
present ≤ 2 mm from the margin, and negative if present > 2 mm
from the margin.
Image analysis
Only specimens with adequate cellularity (³ 10 breast epithelial
cells on Papanicolaou-stained slides, cytology classes II–IV) were
evaluated by image analysis. Sixty-one (64%) specimens were
sufficiently cellular to perform image analysis.
Specimen preparation
A standardized quantitative DNA staining kit (RIAS Feulgen Stain
Kit, Roche Image Analysis Systems, Elon College, NC, USA) was
used following the manufacturer’s instructions. In brief, after
rehydration the slides were processed for hydrolysis with 5 N
hydrochloric acid for 60 min and then transferred to the staining
solution (Schiff’s reagent) for 1 h, rinsed, dehydrated and mounted
with synthetic resin.
Specimen interpretation
The Roche Pathology Workstation (Ellison et al, 1995) was used
to evaluate nuclear ploidy, S phase fraction, % cells in G2/M and
% hypertetraploid cells (cells with greater than twice their comple-
ment of DNA). Human lymphocytes were used as a control diploid
cell population. All epithelial cells if under 100, or a minimum of
100 cells if more were present on a slide, were measured per case
and type of stain. The average number of cells counted per
specimen was 30.
PSA, PGDS, EGF, CEA, testosterone
NAF was extracted from glass capillaries as previously described
(Sauter et al, 1996). The sample was analysed for total protein
with the bicinchoninic acid method (Pierce Chemical Co.,
Rockford, IL, USA).
PSA and PGDS
Both candidate markers in NAF were analysed using a highly
sensitive and specific immunofluorometric procedure (Melegos
et al, 1991; Sauter et al, 1996). The assays use mouse monoclonal
anti-PSA capture antibodies coated to polystyrene microtitre
wells, a biotinylated monoclonal detection antibody, and alkaline
phosphatase-labeled streptavidin (SA-ALP). For each assay,
100 ml of sample is incubated with the coating antibody in the
presence of 50 ml of assay buffer containing the detection anti-
body. After incubation for 1 h and washing ´ 6, the SA-ALP
conjugate is added for 15 min, followed by washing ´ 6. The
activity of ALP is then measured by adding the substrate
5-fluorosalicylphosphate, incubating for 10 min, and by then
adding an EDTA-Tb3+ solution to form a ternary fluorescent
complex between the released 5-fluorosalicylate, Tb3+ and EDTA.
The fluorescence is measured in the time-resolved fluorometric
mode.
EGF, CEA, testosterone
Epidermal growth factor concentration was determined by RIA as
previously described (Lai et al, 1989). The sensitivity of the assay
was 0.04 ng ml–1. CEA was measured by RIA as previously
described (Thompson et al, 1969). Testosterone was quantified first
by extraction with hexane:ethylacetate and subjection to Celite
column partition chromatography prior to RIA (Falk et al, 1996).
Statistical analysis
Spearman’s rank correlation coefficient and Kendall’s tau were
used to determine if there was an association between risk of
residual cancer in the mastectomy specimen and a variety of
candidate markers in NAF: cytology, DNA index (including %
hyper-tetraploid cells), cell cycle parameters (S phase fraction, %
cells in G2/M), PSA, EGF, testosterone and PGDS. Samples were
considered together or by method of diagnosis, and risk of residual
cancer was categorized as either no cancer or residual cancer
(DCIS or invasive cancer). Step-wise logistic regression models
(Agresti, 1990) were fit to the data to determine whether
increasing breast cancer risk categories were associated with cyto-
logical grouping, DNA index, and/or % cells in G2/M. Multiple
risk categorization models were evaluated.
The association between pathologic tumour size and (1) NAF
cytology and (2) method of diagnosis were examined using the c2
test for independence. Differences in quantitative biomarker
expression (PSA, G2/m, EGF, DNA index, hypertetraploidy, CEA,
PGDS, S phase fraction and testosterone) among the specimen
groups defined by tumour size were examined using both para-
metric (t-test, analysis of variance) and non-parametric (Wilcoxon
rank sum and Kruskal–Wallis) test procedures.
RESULTS
The association of residual cancer with a number of candidate
markers of breast cancer risk: S phase fraction, % cells in G2/M, %
hypertetraploid cells, PSA, CEA, EGF, testosterone and PGDS
was evaluated. The markers were initially evaluated separately
based on the method of biopsy, for all 24 specimens in the needle
biopsy group contained residual in situ or invasive cancer within
the breast (lymph node status was not considered), as opposed to
54% (39/72) of mastectomy specimens after excisional biopsy. No
significant differences were identified for any of the markers
based on biopsy method with the exception of cytology (Table 2).
The difference in NAF cytology based on diagnostic method was
not detected when NAF cytology was compared only in mastec-
tomy specimens which contained residual cancer (DCIS or inva-
sive cancer). When samples from both diagnostic groups were
combined and categorized as containing no cancer or residual
cancer, the presence of residual cancer was significantly associ-
ated with abnormal cytology (P = 0.001), % cells in G2/M and
DNA index (both P = 0.01). DNA index was also associated with
NAF cytology (P = 0.0001).
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association with abnormal (class III or IV) NAF cytology. Neither
extensive intraductal component (EIC) nor multifocality and/or
multicentricity (mf/mc) was significantly associated with
abnormal NAF cytology after excisional biopsy. Abnormal NAF
cytology was found in 24% of breast cancers with EIC and in 22%
of cancers with mf/mc compared to 19% of cancers without EIC
and 20% of cancers without mf/mc.
The ability of abnormal (class III–atypical, or class IV–malig-
nant) NAF cytology to predict the presence of residual DCIS or
invasive cancer (residual cancer) was next evaluated. Subjects
were divided by method of diagnosis, for all mastectomy speci-
mens after needle biopsy alone had residual cancer, as opposed to
only 56% after excisional biopsy. Since all mastectomy specimens
from subjects who had undergone needle biopsy alone had residual
cancer, the sensitivity of NAF cytology could not be evaluated.
Eleven of 24 (46%) mastectomies performed after needle biopsy
alone contained class III or IV NAF cytology (Table 2). When
mastectomies performed after excisional biopsy were evaluated,
NAF cytology (class I, II vs class III, IV) was 97% specific (32/33
specimens) in ruling out residual cancer, with the only false posi-
tive coming from a class III cytology specimen (Table 3, Figure 1).
On the other hand, NAF cytology was only 36% sensitive (14/39
specimens) in detecting residual cancer.
Candidate markers in NAF were also evaluated (Table 4) after
specimens were categorized by pathological tumour size (DCIS +
T1 vs T2–4). The T size reflects the best estimate of tumour diameter
considering all diagnostic procedures and the mastectomy speci-
men. Larger tumours were significantly associated with (Table 4,
Figure 2): atypical cytology (P = 0.004), disease diagnosed by
needle biopsy (P = 0.002), higher DNA index (P = 0.03) and %
cells in G2/M (P = 0.05).
When evaluated individually via logistic regression, NAF
cytology, DNA index and % cells in G2/M were found to be signif-
icantly associated with the risk of residual cancer. Forward selec-
tion stepwise logistic regression was implemented to identify a
model based on these three markers which best predicted the pres-
ence of residual cancer in the breast. This resulted in a model
based only on NAF cytology. Thus, the addition of information on
DNA index and/or % cells in G2/M did not significantly improve
the ability to predict residual cancer once NAF cytology was
included in the model.
DISCUSSION
When we initiated this study, we wished to identify markers in
NAF which were associated with residual cancer in the breast, as
well as with tumour size. Because of the difference in the presence
of as well as the quantity of residual tumour in the needle biopsy
and excisional biopsy mastectomy specimens, we felt it important
to analyse the groups separately. As expected, 100% of the mastec-
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Table 2 Nipple aspirate fluid cytology obtained from mastectomy
specimens
Marker NB Ex biopsy1 P-value
Mastectomy diagnosis
Normal, AH, LCIS2 0, 0, 0 25, 4, 3
DCIS2 11 6
Invasive cancer 23 24 0.0001
Cytology (all specimens)
I–II 13 (54%) 57 (79%)
III–IV 11 (46%) 15 (21%) 0.01
Cytology (subjects with residual DCIS or invasive cancer in the mastectomy
specimen)
I–II 13 (54%) 25 (64%)
III–IV 11 (46%) 14 (36%) 0.36
NB, needle biopsy; Ex biopsy, excisonal biopsy; AH, atypical hyperplasia;
LCIS, lobular carcinoma in situ; DCIS, ductal carcinoma in situ.
Table 3 Sensitivity and specificity of nipple aspirate cytology after excisional
biopsy
Residual cancer
Nipple aspirate cytology Yes No
III or IV 14 1








Class I & II Class III Class IV
%
No cancer DCIS Invasive cancer No cancer DCIS Invasive cancer No cancer DCIS Invasive cancer
Figure 1 Association of nipple aspirate cytology (class I–IV) with residual DCIS or invasive cancer after excisional biopsytomies performed after needle biopsy alone had residual DCIS or
invasive cancer, whereas only 39/72 (54%) mastectomies
performed after excisional biopsy contained residual DCIS or
invasive cancer. When separated by method of diagnosis, none of
the biomarkers were significantly different. For this reason, we
did not separate the groups when evaluating the association of
biomarkers with primary tumour size.
When an individual is diagnosed with breast cancer after needle
biopsy, the decision to proceed to mastectomy rather than excisional
biopsy is often based on clinical tumour size, although the estima-
tion may be different from the actual (pathologic) size (Harris et al,
1993). After excisional biopsy, many women undergo mastectomy
for presumed residual cancer, although controversy remains
regarding the necessity to obtain microscopically clear margins
(Hallahan et al, 1989; Veronesi et al, 1990; Sauer et al, 1992,
Anscher et al, 1993). Thousands of women who undergo mastec-
tomy after excisional biopsy will not have in situ or invasive cancer
found in the mastectomy specimen. The chance of finding residual
cancer is related to tumour margin status in the diagnostic specimen.
If the margin is close, the likelihood is 23–32%; if positive,
53–65%; if unknown, approximately 45%, and if negative, approxi-
mately 26% (Frazier et al, 1989; Gwin et al, 1993). It is not unex-
pected that some subjects with negative margins will have residual
cancer, given the possibility of multifocal and/or multicentric
disease. Others have found residual tumour in 32–63% of reexci-
sional biopsies and mastectomies (Schwartz et al, 1984; McCormick
et al, 1987; Schnitt et al, 1987; Olivotto et al, 1989; Stotter et al,
1989).
Invasive breast cancer develops at or near the original biopsy
site in over 25% of patients with DCIS, whereas DCIS is
uncommon (0.2–6%) in randomly selected breasts from autopsy
series (Harris et al, 1993). On the other hand, LCIS left untreated
leads to an increased risk of invasive carcinoma equally distrib-
uted in either breast (Haagensen et al, 1978). These data suggest
that DCIS is a precursor to invasive breast cancer in the area of the
in situ disease, whereas LCIS is a marker of increased risk in either
breast. For the purposes of our analysis, LCIS was not considered
residual cancer if found in the mastectomy specimen.
The breast ducts of adult nonpregnant women secrete small
amounts of fluid (Keynes, 1923). This fluid does not escape
because the nipple ducts are occluded by smooth muscle contrac-
tion, dried secretions, and keratinized epithelium. Breast fluid can
be obtained by nipple aspiration in a significant proportion of
women without spontanous nipple discharge with the use of a
modified breast pump (Petrakis et al, 1975). This fluid contains
several types of cells, including exfoliated breast epithelial cells
(King et al, 1975). Because breast cancer develops from ductal and
lobular epithelium, NAF is a potentially useful epidemiological
and clinical research tool.
Wrensch et al (1992) evaluated NAF in a cohort of subjects with
normal breast cancer risk. In this population, they demonstrated
that subjects with NAF which contained normal cytology, hyper-
plasia without atypia, or atypical hyperplasia have a risk of breast
cancer similar to subjects who have a biopsy with a similar diag-
nosis. We found that malignant (class IV) cells in NAF after exci-
sional biopsy were 100% (7/7 specimens) and atypical (class III)
cells 88% (7/8 specimens) predictive of the presence of residual
breast cancer. NAF cytology, when comparing class III/IV cells
with class I/II cells, was highly associated (P = 0.001) with risk of
residual cancer and with tumour size (P = 0.004).
Computerized image analysis is able to quantitate the DNA
index and cell cycle parameters on a cell by cell basis. The prog-
nostic utility of this modality has been demonstrated for a variety
of tumours, including breast cancer (Dressler et al, 1988). While
flow cytometry is the standard method to determine cellular DNA,
image analysis using Feulgen-stained cell preparations is gaining
increased acceptance because of its ability to evaluate samples of
relatively scant cellularity. DNA indices in epithelial cells from
nipple aspirate specimens were determined and evaluated for their
correlation with cytological class. In a prior study, we reported an
association between both DNA index and % cells in G2/M and
abnormal cytology. The association between these two markers
and breast cancer risk was less clear, although the samples in the
prior study were primarily from subjects with an intact breast. In
NAF from mastectomy specimens, DNA index was significantly
associated with residual cancer, large tumour size and atypical
cytology. In addition, higher % cells in G2/M was significantly
associated with residual cancer and large tumour size.
NAF cytology was highly specific (97% after excisional biopsy)
in ruling out, but not highly sensitive (46% after needle biopsy,
36% after excisional biopsy) in detecting, residual cancer. There
was one false positive, a specimen containing atypical cytology
from a breast not found to contain residual cancer. Given that only
approximately 1% of a mastectomy specimen is evaluated during
routine histological review, it is unknown if this case is truly a
false positive or rather the presence of residual cancer which was
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Table 4 Association of biomarkers with primary tumour sizea
Specimens (Tis, T1)2 (T2–4)2 P-value
Cytology
I, IIA, IIB 69 39 30
III, IV 26 6 20 0.004
Median % Cells in G2/M 63 1.79 5.07 0.05
Median DNA index 63 1.11 1.31 0.03
aTumour size: includes subjects diagnosed by either needle or excisional
biopsy. (Tis, T1, T2–4)2: Tis-carcinoma in situ; T1: tumour ≤ 2 cm; T2–4: tumour >
2 cm and/or with direct extension to the chest wall or skin. Complete TNM









Figure 2 Percentage of specimens with abnormal (class III–IV) nipple
aspirate cytology based upon primary tumour sizeNAF to identify markers of breast cancer 1227
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not identified on routine evaluation.
Although abnormal cytology was highly predictive of residual
cancer, abnormal cytology was detected in only 36% of specimens
with residual DCIS or invasive cancer. As such, while a finding of
abnormal cytology is highly suggestive of the presence of residual
cancer, normal cytology does not exclude the possibility that
residual cancer exists. We therefore evaluated the two other
markers (DNA index and % cells in G2/M) which were associated
with residual cancer, in an attempt to increase our ability to predict
if residual cancer exists. While neither marker increased the
predictive ability of NAF cytology alone, we are currently evalu-
ating other candidate markers, including insulin-like growth factor
type 1 (IGF-1) and IGF binding protein type 3, to determine if
these markers, when combined with cytology, will improve our
ability to use NAF markers to predict residual cancer in the
mastectomy specimen.
In summary, NAF can be obtained from mastectomy specimens
and biological markers of breast cancer risk evaluated with a high
degree of success. Both abnormal cytology and higher DNA index
were associated with tumour progression. DNA index was associ-
ated with atypical cytology. Atypical cytology, DNA index and
% cells in G2/M were each associated with residual cancer.
Malignant cytology was 100% and atypical cytology 88% predic-
tive of residual DCIS or invasive cancer after excisional biopsy.
These findings provide insight into breast cancer tumour develop-
ment and progression, and may prove useful in guiding therapy.
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